LAUSR

Cairo, M.S. & Bishop, M. (2004) Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology, 127, 3–11. Coiffier, B., Mounier, N., Bologna, S., Ferm e, C., Tilly, H., Sonet, A., Christian, B., Casasnovas, O., Jourdan, E., Belhadj, K. & Herbrecht, R. (2003) Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. Journal of Clinical Oncology, 21, 4402–4406. Davidson, M.B., Thakkar, S., Hix, J.K., Bhandarkar, N.D., Wong, A. & Schreiber, M.J. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. American Journal of Medicine, 116, 546–554. Feng, X., Dong, K., Pham, D., Pence, S., Inciardi, J. & Bhutada, N.S. (2013) Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a metaanalysis. Journal of Clinical Pharmacy and Therapeutics, 38, 301–308. Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. & Cairo, M.S. (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 97, 2998–3003. Jones, G.L., Jones, G.L., Will, A., Jackson, G.H., Webb, N.J. & Rule, S. (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for standards in Haematology. British Journal of Haematology, 169, 661–671. Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemeister, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N., Shah, J., Orlowski, R.Z., Samaniego, F., Wang, M., Cortes, J.E., Younes, A., Kwak, L.W., Sarlis, N.J. & Romaguera, J.E. (2012) A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Annals of Oncology, 23, 1640–1645. Wu, X.W., Lee, C.C., Muzny, D.M. & Caskey, C.T. (1989) Urate oxidase: primary structure and evolutionary implications. Proceedings of the National Academy of Sciences of the United States of America, 86, 9412–9416.